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Summary
We undertook a population-based case-control study to test
the clinical importance of a hereditary abnormality in the
coagulation System, characterised by poor anticoagulant
response to activated protein C (APC), which is associated with
familial thrombophilia.
The abnormality was detected in 64 (21%) of 301
unselected consecutive patients younger than 70 years, with a
first, objectively confirmed episode of deep-vein thrombosis
and without underlying malignant disease. Among 301
healthy control subjects matched for age and sex, the
frequency was 5% (14 subjects). Thus, there is a seven-fold
increase in risk of deep-vein thrombosis in subjects with a poor
response to APC (matched odds ratio 66 [95% Cl
3 6-12 0]). In addition, there was a clear inverse relation
between the degree of response to APC and thrombosis risk. In
the families of the patients an autosomal dominant mode of
transmission of the abnormality was confirmed. 9 of 10
thrombosis patients with a poor response to APC had l parent
with a similar poor response, whereas 9 of 10 patients with
normal tests had parents with equally normal tests. The
abnormality was found in both parents of l patient with an
extremely poor response to APC; this patient is probably
homozygous for the abnormality.
We conclude that the poor response to APC is the most
important hereditary cause of venous thrombosis. Its high
prevalence in a series of unselected patients will make testing
of all thrombosis patients for this abnormality worth while.
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Introductlon
Deep-vein thrombosis is a common disease. Well-
established risk factors include recent surgery, malignant
disorders, pregnancy and labour, long-term immobil-
isation, and deficiency of one of the main Inhibitors of the
clotting System—protein C, protein S, or antithrombin
III.1 However, the causes of deep-vein thrombosis in many
patients are unclear. Dahlbäck et al2 reported earlier this
year a poor anticoagulant response to activated protein C
(APC) in several families with a hereditary tendency to
venous thrombosis.
The anticoagulant property of APC lies in its capacity to
inactivate the activated cofactors Va and Villa by limited
proteolysis.3 It has been generally accepted that this
reaction proceeds optimally only in the presence of calcium
ions, phospholipids, and the APC co-factor, protein S.4
However, this view has been challenged by the finding that
in Systems of purified proteins, protein S has hardly any
co-factor activity to APC.5·6 A possible explanation for the
discrepancy between in-vivo observations (thrombotic
tendency in hereditary protein S deficiency) and the
findings in vitro may be provided by Dahlbäck and
colleagues' findings.2 In their thrombotic patients, addition
of APC to plasma did not result in the expected
Prolongation of the activated pärtial thromboplastin time
(APTT). After ruling out several other theoretical
possibilities that could have provoked the poor
anticoagulant response to APC, Dahlbäck et al postulated
deficiency in these patients of a hitherto unknown co-factor
to APC.
Studies within families suggest that the poor response to
APC is inherited äs an autosomal dominant trait.2·7 Among
patients referred to a coagulation unit because of
unexplained thrombosis, this abnormality was an
important cause of thrombophilia, with a prevalence of
about40%.8·9
We have investigated the clinical importance of the poor
response to APC in 301 unselected patients with a first,
objectively confirmed episode of deep-vein thrombosis and
without. underlying malignant disease, by comparing their
sensitivity to APC with that of matched healthy controls.
The study was part of a population-based case-control
study on hereditary venous thrombosis, the Leiden
Thrombophilia Study (LETS).
Patients and methods
Patients were selected from the files of thrombosis centres in
Leiden, Amsterdam, and Rotterdam. In the Netherlands,
thrombosis centres monitor coumarin treatment in virtually all
patients with venous thrombosis, each for patients in a defmed
geographical area.10 Since all our patients originated from one of
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these areas, geography was the only cntenon for entry We
mcluded the first 345 consecutive outpatients younger than 70
years, who were referred for anticoagulant treatment because of a
first, objectively confirmed episode of deep-vem thrombosis that
occurred between Jan l, 1988, and Dec 31, 1992 Patients with
known mahgnant disorders were excluded Information about the
mclusion and exclusion cnteria was obtamed from general
practitioners and from hospital dtscharge records Patients were
seen only after anticoagulant treatment had been discontmued for
at least 3 months The median time between the occurrence of
deep-vem thrombosis and venepuncture for this study was 18
(ränge 6-48) months 90% of eligible patients were willmg to take
pari m the study
Each thrombosis patient was asked to find his or her own healthy
control subject according to the followmg cnteria same sex, the
same age (plus or minus 5 years), no biological relationship, no
history of venous thromboembohsm, no use of coumanns for at
least 3 months, and no known mahgnant disorders Partners of
patients were also invited to serve äs control subjects When a
patient was unable to find a control, the first individual from the hst
of partners who matched for age and sex was asked to jom the study,
126 (42%) control subjects were partners of patients
To confirm an autosomal dominant mode of transmission and to
exclude the possibility of a post-thrombotic phenomenon, we
assessed the response to APC in the parents of the first 10 eligible
patients with poor responses to APC and m the parents of 10
randomly selected patients with normal responses to APC These
patients were matched for sex and all came from the Leiden area
We also tested the parents of l patient with an extremely poor
response to APC (APC-sensitivity ratio l 21)
All patients and control subjects were seen by one of us (T K)
Blood was collected from the antecubital vem into 0 106 mmol/L
tnsodium citrate Plasma was prepared by centnfugation for 10
min at 2000 £ at room temperature and stored at - 70°C, in l 5 mL
volumes
The sensitivity of the plasma APTT to APC was measured äs
descnbed by Dahlback et al,2 with the reagents and reaction
schemes developed for the protein S activity assay " Bnefly, 50 μι,
undiluted plasma was mcubated with 50 μι APTT reagent
(Cephotest, Nycomed Pharma, Oslo, Norway) for 360 s at 37°C
Clot formation was started with either 50 μΐ^ of 33 mmol/L calcium
Chloride, 25 mmol/L tris-HCl (pH 7 5), 50 mmol/L sodium
Chloride, and 0 05", ovalbumm (APTT, - APC) or 50 μι of the
same reagent also contammg 2 0 μg/mL human APC and 0 6°,
glycerol (APTT, + APC) Automated analysis was done in an
ACL-300 (Instrumentation Laboratory, Milan, Italy), with the
research program Results are expressed äs APC-sensitivity ratios,
defined äs APTT ( +APC) divided by the APTT (- APC) The
APC-sensitivity ratio of plasma is stable for at least 2 h after
thawmg and is not sigmficantly affected by two subsequent cycles
of freezing and thawmg Routmely, plasma was analysed withm l h
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Figure 2 APC-sensitivity ratios of thrombosis patients and
controls
of thawmg Under these conditions, the APC-sensitivity ratio for
pooled normal plasma is 2 67 and the between-assay Variation is 4" „
(n = 8) APC-sensitivity ratio is independent of protein S levels
above 0 2 u/mL, and plasma completely depleted of protein S
(<0001 u/mL) still has an APC-sensitivity ratio of 2 l Low
concentrations of prothrombin, factor X, or both ( < 0 5 u/mL)
increase the APC-sensitivity ratio, so the test cannot be used for
patients receivmg oral anticoagulants In a series of 98 samples we
found a good correlation (Pearson correlation coefficient 0 54)
between the APC-sensitivity ratios obtamed with our test and
those obtamed with a test developed by Chromogemx (Molndal,
Sweden) Additionally, in 20 samples sent to us by Chromogemx,
the Pearson correlation coefficient was 0 79 APC was prepared
from isolated human protein C äs previously descnbed,12 and
stored in small volumes at — 30°C in a buffer contammg 50 mmol/L
tris-HCl (pH 7 5), 100 mmol/L sodium chlonde, 0 l % ovalbumm,
and 7 5"„ glycerol
Other coagulation assays were done according to estabhshed
procedures Protein C activity was measured with Coamate
(Chromogemx) on an ACL-200, total protein S by an enzyme-
linked immunosorbent assay (ELISA),11 factor VIII coagulant
activity by a one-stage clottmg assay with artificial FVII I-deficient
plasma, and automated APTT (Organon Teknica, Durham, NC,
USA) on an Electra 1000 (MLA, Pleasantville, USA) The
technicians were at all times unaware of the Status of the sample
42 patients were on long-term coumann treatment, includmg 15
(36 ', ) who had had recurrent thrombosis before joining the study
2 patients mitially had prolonged APTT consistent with lupus
anticoagulant After exclusion of these 44 subjects, our sample
consisted of 301 patient-control pairs
A reference ränge for the APC-sensitivity ratio was derived from
the 301 healthy control subjects After loganthmic transformation
of the data and exclusion of 10 subjects with values outside 3 SD
below or above the mean, the lower hmit of normal was 2 1 7 (mean
minus l 96 SD)
We analysed the effect of age (contmuous variable) and sex (0
women, l men) on the natural log-transformed APC-sensitivity
ratio outcome in the healthy controls with a normal response to
APC (5=2 17) by multiple linear regression techniques The
regression coefficient obtamed shows the increase or decrease in
the logarithm of the APC-sensitivity ratio outcome per unit
increase m the factor studied, adjusted for the effect of other
variables in the model
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Age group (yr)
<-25
25-34
35-44
45-54
^54
No of patients
19
52
58
87
85
Mo (%) poor responders
8(42)
11(21)
11(19)
14(16)
20(24)
Table 1: Age-specific prevalence of poor response to APC in
301 thrombosis patients
We calculated crude matched odds ratios äs estimates of the
relative risk by simple cross tabulation. We used Miettinen's
test-based 95",, CI.U The odds ratio reflects the thrombosis risk
when the APC-sensitivity ratio is too low in comparison with the
risk when the ratio is within the normal ränge, adjusted for age and
sex. We also sought a dose-response relation, by calculating odds
ratios over several strata of APC-sensitivity ratio. We used a
conditional logistic model (Egret Software), which allows
adjustment for several factors (eg, factor VIII:C, fibrinogen,
protein C, and protein S) simultaneously.
Results
The male/female ratio among patients and controls was
1/1-5 and mean age was 46 years (ränge 17-70 patients,
17-73 controls).
Among the controls, at all ages, men had a more
pronounced anticoagulant response to APC than women
(regression coefficient for natural logarithm of APC-
sensitivity ratio 0-05 [95% CI 0-03-0-08]). Age also seemed
to be a determinant of the APC-sensitivity ratio (regression
coefficient -0-002 [-0-001 to -0-003], figure 1).
None of the 602 subjects had an APC-sensitivity ratio
between l -8 and 2-0 (figure 2). This gap cannot beexplained
by digit preference, since the result is given by automated
Computer Output. We take it to be evidence of strongly
bimodal distribution. 64 (21%) of the patients showed
a poor response to APC (APC-sensitivity ratio below
2-17). Only 14 (5%) of the 301 healthy control subjects
had a poor response. There were 68 discordant patient-
control pairs, in 59 of which the patient had an abnormal
APC-sensitivity ratio and the control subject did not. The
abnormality was evenly distributed among age groups
(table 1).
The crude (matched) odds ratio for a poor response to
APC was 6-6 (95% CI 3-6-12-0)—ie, an almost seven-fold
increase in risk of thrombosis associated with a poor
response to APC. Table 2 gives the odds ratios for the strata
of APC-sensitivity ratios. It shows a relation between the
risk of thrombosis and the degree of response. Adjustment
for factor VIII:C, protein C, protein S, or fibrinogen
concentrations did not change the reported odds ratios.
Among the subjects with a poor response to APC there was
no one with protein S deficiency, and only l individual with
a possible protein C deficiency.
We have summarised the results of the family studies in
figure 3. For 9 of the 10 patients with a normal response to
APC, both parents had normal responses too. l patient with
a normal response to APC (sensitivity ratio 2-38) had one
APC-sensIttvIty
^1 5
20-2 5
1 5-2 0
<1 5
Patients
163
84
36
18
Controls
220
72
7
2
Odds ratio
(95% CI)*
1
16(1 1-2 4)
74(30 -180 )
12 0 (2 7-56 0)
g
2 30-1
g 20-1
t f.
father
mothei
Parents ot patients
with normal response
to APC
Parents of patients
with poor response
to APC
Parents of 1 patient
with very poor
response to APC
* Matched (crude) odds ratio, adjustment (or tactor VIII-C, protein C, or protein S
concentrations or fibrinogen did not affect these results Test for trend, p < 0 001
Table 2: Thrombosis risk for strata of APC-sensitivity ratios
( 225317 ) (146-210) (121)
Figure 3: APC-sensitivity ratios of parents of thrombosis
patients by response to APC
Pairs of parents indicated by broken hnes. Horizontal solid hne represents
Iower limit of normal APC-sensitivity ratio. Fisher's exact test of offspring
response by parent response p = 0 001.
parent with a low APC-sensitivity ratio (1-64). With a
prevalence of 5% in control subjects, we expected to find
one parent with a poor response to APC. Among the
patients with poor responses, all but l had one parent with a
poor response to APC and one parent with a normal
response. Both parents of the remaining patient had a
normal test outcome. This pattern could be the result of a
new mutation, laboratory errors, a non-biological parent, or
the presence of an overlap-area in which true heterozygotes
and normal individuals cannot be separated on the APC-
sensitivity ratio. The subject's APC-sensitivity ratio was
only slightly low (2-10), whereas all the other patients in this
subgroup had APC-sensitivity ratios between 1-46 and
1-76. Figure l shows that when the APC-sensitivity ratio is
1-9 or less, there is little doubt that a person is a poor
responder. We found 6 patients who had very low APC-
sensitivity ratios (< 1-25). The parents of only l of these
patients could be tested; both had a poor response to APC.
It is likely that this patient was homozygous or double
heterozygous for the abnormality, and that this state is
associated with an even greater risk of thrombosis than is
the heterozygous state (table 2).
Discussion
The 21% prevalence of a poor response to APC among
thrombosis patients and the odds ratio for thrombosis of 6-6
lead to the conclusion that a poor response to APC is a
common and strong risk factor for deep-vein thrombosis.
Both age and sex are determinants of the APC-sensitivity
ratio in normal individuals, although the differences are
quite small.
The pattern in the parents of the patients was compatible
with the reported dominant heredity of the abnormality.2·7
We speculate that subjects with APC-sensitivity ratios
around 1-10 are homozygous or double heterozygous,
whereas subjects with APC-sensitivity ratios around 1-50
are heterozygous for the abnormality. This notion could
explain the apparent "dose-response" shown in table 2, and
our fmding that the APC-sensitivity ratio of a l /1 mixture of
pooled normal plasma and plasma of a presumed
homozygote is l -60.
An important point in the assessment of case-control
studies is the selection of patients and control subjects.
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Since we were interested in the risk of a first episode of
deep-vein thrombosis, we opted for mcident cases. 42
patients were excluded because they were receiving long-
term coumarin treatment; a substantial percentage of them
had had recurrent thrombosis before the study. If these
subjects have a higher Chance of having a poor response to
APC, our estimates may be conservative. Svensson et al8
found a much higher prevalence—40% of selected patients
with deep-vein thrombosis. We believe that this difference
is due to the selection of the patients. The subjects in
Svensson's study were referred from the south of Sweden
with unexplained thrombosis.89 The control subjects were
selected by our patients. We do not think that this practice
can have biased our findings on this new abnormality in the
coagulation System.
The prevalence of the abnormality was 5 % among the
healthy control subjects. Because distribution was clearly
bimodal, we believe these subjects really did have abnormal
responses to APC rather than low values within a normal
ränge. The relation between risk of thrombosis and the
response to APC seems therefore not to follow the model of
a simple single-gene deficiency. Because the abnormality is
so prevalent in healthy subjects, it is unlikely that the defect
in itself is sufficient to cause thrombosis, äs is true also for
protein C deficiency.1516 Other causal factors seem to be
required for the development of thrombosis; these may be
acquired factors or äs yet unknown genetic defects or
variations. However, when other causal factors are present,
poor APC response strongly increases the risk of
thrombosis.
The underlying defect of the poor response to APC
remains unclear, even though a deficiency of a co-factor to
APC with autosomal dominant inheritance has been
postulated.7 Although a poor response to APC appears
to be about 5-10 times more frequent than deficiencies of
protein C, protein S or antithrombin III, it confers a similar
relative risk of thrombosis.17 ls It may well be worth while to
test all patients with venous thrombosis for this
abnormality.
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